263 related articles for article (PubMed ID: 30218958)
1. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
Santibanez M; Lesch CA; Lin L; Berger K
J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
[TBL] [Abstract][Full Text] [Related]
2. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
5. A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage.
Berger K; Santibañez M; Lin L; Lesch CA
J Intensive Care Med; 2020 Nov; 35(11):1203-1208. PubMed ID: 30983472
[TBL] [Abstract][Full Text] [Related]
6. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
8. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
[TBL] [Abstract][Full Text] [Related]
9. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
11. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
Rech MA; Masic D; Hammond DA
West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
[TBL] [Abstract][Full Text] [Related]
12. Off-label use of 4-factor prothrombin complex concentrate is common despite little known benefit: A retrospective study.
Scharman CD; Shatzel JJ; Kim E; DeLoughery TG
Eur J Haematol; 2018 Sep; 101(3):349-353. PubMed ID: 29862565
[TBL] [Abstract][Full Text] [Related]
13. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal.
Voils SA; Holder MC; Premraj S; Catlin JR; Allen BR
Thromb Res; 2015 Sep; 136(3):595-8. PubMed ID: 26233569
[TBL] [Abstract][Full Text] [Related]
17. Periprocedural warfarin reversal with prothrombin complex concentrate.
Sridharan M; Wysokinski WE; Pruthi R; Oyen L; Freeman WD; Rabinstein AA; McBane RD
Thromb Res; 2016 Mar; 139():160-5. PubMed ID: 26657301
[TBL] [Abstract][Full Text] [Related]
18. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
19. Emergent reversal of vitamin K antagonists: addressing all the factors.
Martin DT; Barton CA; Dodgion C; Schreiber M
Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
[TBL] [Abstract][Full Text] [Related]
20. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
